Francesco Iorio

Active 2005–2025

93
Papers
23,522
Citations
46
h-index
73
i10-index

Citations

Citations per year for Francesco Iorio1991: 1 citations1994: 1 citations1997: 2 citations2000: 1 citations2001: 1 citations2002: 2 citations2003: 2 citations2006: 3 citations2007: 2 citations2008: 11 citations2009: 17 citations2010: 56 citations2011: 76 citations2012: 119 citations2013: 159 citations2014: 200 citations2015: 245 citations2016: 322 citations2017: 378 citations2018: 427 citations2019: 1,010 citations2020: 1,421 citations2021: 1,554 citations2022: 1,246 citations2023: 867 citations2024: 1,340 citations2025: 747 citations2026: 77 citations1992–1993: no citations, so these years are not shown1995–1996: no citations, so these years are not shown1998–1999: no citations, so these years are not shown2004–2005: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,288 citing papers, 22.5% of this breakdownChina: 1,875 citing papers, 12.8% of this breakdownUnited Kingdom: 1,162 citing papers, 7.9% of this breakdownGermany: 830 citing papers, 5.7% of this breakdownItaly: 668 citing papers, 4.6% of this breakdownNetherlands: 497 citing papers, 3.4% of this breakdownIndia: 426 citing papers, 2.9% of this breakdownCanada: 421 citing papers, 2.9% of this breakdownSpain: 409 citing papers, 2.8% of this breakdownFrance: 373 citing papers, 2.5% of this breakdownJapan: 347 citing papers, 2.4% of this breakdownAustralia: 316 citing papers, 2.2% of this breakdown
0%22.5%Other 27.4%

Fields

  • Biochemistry, Genetics and Molecular Biology38.3%
  • Medicine31.7%
  • Computer Science18.1%
  • Engineering4.1%
  • Immunology and Microbiology1.6%
  • Physics and Astronomy1.4%
  • Other4.8%

Topics

  • Computational Drug Discovery Methods7.3%
  • Bioinformatics and Genomic Networks5.2%
  • Cancer Genomics and Diagnostics3.9%
  • Cancer Cells and Metastasis3.2%
  • CRISPR and Genetic Engineering2.1%
  • Gene expression and cancer classification2%
  • Other76.3%

Coauthors

All papers

Open in search
  1. Drug repurposing: progress, challenges and recommendations

    Authors: , , , , , , , , , , , , , - Nature Reviews Drug Discovery 2018 cited by 4,668

  2. Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gad Getz, Lodewyk F.A. Wessels, Michael R. Stratton, Ultan McDermott, Matthew Meyerson, Mathew J. Garnett, Hans Clevers - Cell 2015 cited by 2,472

  3. A Landscape of Pharmacogenomic Interactions in Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Manel Esteller, Nathanael S. Gray, Daniel A. Haber, Michael R. Stratton, Cyril H. Benes, Lodewyk F.A. Wessels, Julio Sáez-Rodríguez, Ultan McDermott, Mathew J. Garnett - Cell 2016 cited by 2,304

  4. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2019 cited by 1,455

  5. Systematic identification of genomic markers of drug sensitivity in cancer cells

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Tinghu Zhang, Patrick O’Brien, Jessica L. Boisvert, Stacey Price, Wooyoung Hur, Wanjuan Yang, Xianming Deng, Adam P. Butler, Hwan Geun Choi, Jae Won Chang, José Baselga, Ivan Stamenkovic, Jeffrey A. Engelman, Sreenath V. Sharma, Olivier Delattre, Julio Sáez-Rodríguez, Nathanael S. Gray, Jeffrey Settleman, P. Andrew Futreal, Daniel A. Haber, Michael R. Stratton, Sridhar Ramaswamy, Ultan McDermott, Cyril H. Benes - Nature 2012 cited by 2,601

  6. Convolutional Neural Networks for Steady Flow Approximation

    Authors: , , - SIGKDD International Conference on Knowledge Discovery and Data Mining 2016 cited by 701

  7. A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Cell Reports 2016 cited by 834

  8. Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mathew J. Garnett, Ultan McDermott, Serena Nik‐Zainal, Peter J. Campbell, Michael R. Stratton - Cell 2019 cited by 450

  9. Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties

    Authors: , , , , , , - PLoS ONE 2013 cited by 567

  10. Phenotypic plasticity and genetic control in colorectal cancer evolution

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Luca Magnani, Andrea Sottoriva, Trevor A. Graham - Nature 2022 cited by 182

  11. Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2019 cited by 282

  12. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thierry Façon, P. Andrew Futreal, Kenneth C. Anderson, Peter J. Campbell, Nikhil C. Munshi - Nature Communications 2014 cited by 906

  13. Discovery of drug mode of action and drug repositioning from transcriptional responses

    Authors: , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2010 cited by 852

  14. Combinatorial CRISPR screen identifies fitness effects of gene paralogues

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 cited by 136

  15. Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets

    Authors: , , , , , , , , , - Nucleic Acids Research, Nucleic Acids Res. 2020 cited by 128

  16. Pharmacogenomic agreement between two cancer cell line data sets

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2015 cited by 444

  17. A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2024 cited by 91

  18. Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Molecular Systems Biology 2020 cited by 112

  19. Cancer research needs a better map

    Authors: , , , , , , , , , - Nature 2021 cited by 107

  20. Minimal genome-wide human CRISPR-Cas9 library

    Authors: , , , , , , , , , , , , , , , , - Genome biology 2021 cited by 95

  21. Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer

    Authors: , , , , , , , , , , , , , - Cancer Research 2017 cited by 235

  22. CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines

    Authors: , , , , , , , , , , , , , , , , - iScience 2018 cited by 166

  23. Logic models to predict continuous outputs based on binary inputs with an application to personalized cancer therapy

    Authors: , , , , , , - Scientific Reports 2016 cited by 69

  24. Integrated cross-study datasets of genetic dependencies in cancer

    Authors: , , , , , , , , , , , , , - Nature Communications 2020 cited by 339